The ovarian cancer market is expected to grow significantly owing to an increase in diagnosed cases, increased awareness about the disease, increased R&D for developing new molecules, and the expected commercial success of upcoming therapies in the 7MM
LAS VEGAS, April 12, 2023 /PRNewswire/ -- DelveInsight's Ovarian Cancer Market Insights report includes a comprehensive understanding of current treatment practices, ovarian cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Ovarian Cancer Market Report
- As per DelveInsight analysis, the ovarian cancer market is expected to grow positively at a significant CAGR during the study period (2019-2032).
- According to the Centers for Disease Control and Prevention (CDC) (2022), ovarian cancer is a group of diseases that originates in the ovaries or the related areas of the fallopian tubes and the peritoneum; it accounts for only 3% of cancers in women.
- Leading ovarian cancer companies such as Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others are developing novel ovarian cancer drugs that can be available in the ovarian cancer market in the coming years.
- Some key therapies for ovarian cancer treatment include Stenoparib (2X-121), Adavosertib (AZD-1775), Tedopi (OSE 2101), CriPec (CPC634), OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), Batiraxcept (AVB-500), Upifitamab Rilsodotin (XMT-1536), RUBRACA (rucaparib), Avutometinib (VS-6766), Vigil, Ofra-vec (ofranergene obadenovec; VB-111), Veliparib (ABT-888), Seribantumab, IMFINZI (durvalumab), Oregovomab, Nemvaleukin alfa, ROZLYTREK (entrectinib), LYNPARZA (olaparib), ZEJULA (niraparib), Maveropepimut-S (DPX-Survivac), Relacorilant (CORT125134), and others.
- The emerging ovarian cancer therapies are in the mid-phase of their clinical trials and are awaiting a launch to make the pipeline robust.
Discover which therapies are expected to grab the major ovarian cancer market share @ Ovarian Cancer Market Report
Ovarian Cancer Overview
Ovarian cancer refers to a group of diseases that begin in the ovaries or nearby areas of the fallopian tubes and peritoneum. It is responsible for only 3% of all cancers in women. Ovarian cancer is malignant or cancerous cells that affect ovaries tissues. Ovarian cancer is now recognized as several distinct diseases, each named after the type of cell origin: epithelial, germ cell, and stromal. The most common type of ovarian cancer is epithelial ovarian cancer. The exact ovarian cancer cause is unknown.
Ovarian cancer frequently has warning signs, but early ovarian cancer symptoms are vague and easily dismissed. The ovarian cancer symptoms are frequently subtle and easily confused with other, more common problems. Bloating, pelvic pain, frequent urination, and feeling full quickly with eating are early symptoms, while advanced symptoms include changes in bowel habits, back pain, ascites, fatigue, and others. There is no single test for ovarian cancer diagnosis; instead, physicians consider the symptoms in conjunction with the results of the patient history, physical examination, biopsies, blood tests, and imaging scans (ultrasound, CT, and MRI).
Ovarian Cancer Epidemiology Segmentation
According to DelveInsight's estimate, the total diagnosed incident cases of ovarian cancer in the 7MM comprised 58K cases in 2022 and are projected to reach up to 46K cases by 2032. These cases are anticipated to decrease during the study period.
As per the estimates, in EU4 and the UK, the highest number of total diagnosed incident cases of ovarian cancer was observed in Germany in 2022.
The ovarian cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Total Ovarian Cancer Diagnosed Incident Cases
- Ovarian Cancer Age-specific Cases
- Ovarian Cancer Type-specific Cases
- Ovarian Cancer Stage-specific Cases
- Ovarian Cancer Line-wise Treated Cases
Download the report to understand which factors are driving ovarian cancer epidemiology trends @ Ovarian Cancer Epidemiological Insights
Ovarian Cancer Treatment Market
Currently, the most effective therapeutic agents against newly diagnosed ovarian cancer are platinum analogs, such as cisplatin or carboplatin, combined with a taxane, such as paclitaxel or docetaxel. Primary surgical cytoreduction (to debulk tumors) followed by combination platinum-based chemotherapy or chemotherapy before surgery (neoadjuvant therapy) followed by interval surgical cytoreduction and additional chemotherapy after surgery are both options for first-line newly diagnosed ovarian cancer treatment.
Women with advanced-stage ovarian cancer frequently experience recurrence after the initial platinum-based chemotherapy, and most patients have shown resistance to platinum-based chemotherapy. However, recent advances in new therapeutics for recurrent ovarian cancer treatment have shown promising results. Angiogenesis inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and others are among the new ovarian cancer treatment options.
Given the disease's recurrence and progression, proper management and ovarian cancer treatment methods are required, which may include checkpoint inhibitors, targeted therapies, and other angiogenesis inhibitors. Proper ovarian cancer treatment methods, such as pharmacological treatments and other techniques, are required to prevent the recurrence and progression of this deadly disease. With current ovarian cancer therapies and well-defined screening programs for ovarian cancer, there is still a significant unmet need. OC is often misdiagnosed until it is advanced, at which point the disease becomes extremely aggressive and easily progresses into other deadly stages.
To know more about ovarian cancer treatment, visit @ Ovarian Cancer Treatment Drugs
Key Ovarian Cancer Therapies and Companies
- Stenoparib (2X-121): Allarity Therapeutics
- Adavosertib (AZD-1775): AstraZeneca
- Tedopi (OSE 2101): OSE Immunotherapeutic
- CriPec (CPC634): Cristal Therapeutics
- OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceuticals
- KEYTRUDA (pembrolizumab): Merck & co
- Batiraxcept (AVB-500): Aravive Biologics
- Upifitamab Rilsodotin (XMT-1536): Mersana Therapeutics
- RUBRACA (rucaparib): Clovis Oncology
- Avutometinib (VS-6766): Verastem Oncology
- Vigil: Gradalis
- Ofra-vec (ofranergene obadenovec; VB-111): VBL Therapeutics
- Veliparib (ABT-888): AbbVie
- Seribantumab: Elevation oncology
- IMFINZI (durvalumab): AstraZeneca
- Oregovomab: OncoQuest Pharmaceuticals (CanariaBio)
- Nemvaleukin alfa: Alkermes
- ROZLYTREK (entrectinib): Hoffman-la Roche
- LYNPARZA (olaparib): AstraZeneca/MSD
- ZEJULA (niraparib): GlaxoSmithKline
- Maveropepimut-S (DPX-Survivac): IMV
- Relacorilant (CORT125134): Corcept Therapeutics
Learn more about the FDA-approved drugs for ovarian cancer @ Drugs for Ovarian Cancer Treatment
Ovarian Cancer Market Dynamics
The dynamics of the ovarian cancer market are expected to change in the coming years owing to an increase in diagnosed cases, increased awareness about the disease, and others. Advocacy organizations such as the International Gynecologic Cancer Society (IGCS) and the World Ovarian Cancer Coalition (WOCC) have launched campaigns to raise awareness and educate women about ovarian cancer. These programs disseminate information about ovarian cancer risk factors, symptoms, recommended screening, and prevention strategies.
Moreover, the rapid advancement in R&D will cater to the lack of early-stage diagnosis; hence, more patient pools will be available for clinical studies and treatment in the ovarian cancer market. Furthermore, the ovarian cancer pipeline is very robust; many potential therapies are being investigated for the treatment of ovarian cancer, and it is safe to predict that the treatment space will significantly impact the ovarian cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the ovarian cancer market in the 7MM.
However, several factors are impeding the growth of the ovarian cancer market. The wide use of generics as a standard of care treatment for ovarian cancer may threaten the growth of the ovarian cancer market. Moreover, ovarian cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the ovarian cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the ovarian cancer market growth.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Base Year | 2019 |
Key Ovarian Cancer Companies | Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others |
Key Ovarian CancerTherapies | Stenoparib (2X-121), Adavosertib (AZD-1775), Tedopi (OSE 2101), CriPec (CPC634), OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), Batiraxcept (AVB-500), Upifitamab Rilsodotin (XMT-1536), RUBRACA (rucaparib), Avutometinib (VS-6766), Vigil, Ofra-vec (ofranergene obadenovec; VB-111), Veliparib (ABT-888), Seribantumab, IMFINZI (durvalumab), Oregovomab, Nemvaleukin alfa, ROZLYTREK (entrectinib), LYNPARZA (olaparib), ZEJULA (niraparib), Maveropepimut-S (DPX-Survivac), Relacorilant (CORT125134), and others |
Scope of the Ovarian Cancer Market Report
- Therapeutic Assessment: Ovarian Cancer current marketed and emerging therapies
- Ovarian Cancer Market Dynamics: Attribute Analysis of Emerging Ovarian Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement
Discover more about ovarian cancer drugs in development @ Ovarian Cancer Clinical Trials
Table of Contents
1. | Ovarian Cancer Market Key Insights |
2. | Ovarian Cancer Market Report Introduction |
3. | Ovarian Cancer Market Overview at a Glance |
4. | Ovarian Cancer Market Executive Summary |
5. | Disease Background and Overview |
6. | Ovarian Cancer Treatment and Management |
7. | Ovarian Cancer Epidemiology and Patient Population |
8. | Patient Journey |
9. | Ovarian Cancer Marketed Drugs |
10. | Ovarian Cancer Emerging Drugs |
11. | Seven Major Ovarian Cancer Market Analysis |
12. | Ovarian Cancer Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Ovarian Cancer Market Drivers |
16. | Ovarian Cancer Market Barriers |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Related Reports
Ovarian Cancer Epidemiology Forecast
Ovarian Cancer Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted ovarian cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Ovarian Cancer Pipeline
Ovarian Cancer Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Gradalis, VBL Therapeutics, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, among others.
Advanced Ovarian Cancer Pipeline
Advanced Ovarian Cancer Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced ovarian cancer companies, including OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., among others.
Epithelial Ovarian Cancer Pipeline
Epithelial Ovarian Cancer Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epithelial ovarian cancer companies, including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, among others.
Advanced Recurrent Ovarian Cancer Market
Advanced Recurrent Ovarian Cancer Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced recurrent ovarian cancer companies, including IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast-by 2035 | Glioblastoma Market
Related Healthcare Blogs
Upcoming Oncological Drugs in 2023
Metastatic Castration-Sensitive Prostate Cancer Treatment Market
Checkpoint Inhibitor Refractory Cancer Market
Promising Oncolytic Virues Candidates in Pipeline
ENHERTU's Journey in Cancer Treatment and Management
Potential of PD-1 and PD-L1 Inhibitors in Cancer Management
Evolving EGFR NSCLC Treatment Market Dynamics
Emerging Role of Digital Health in the Field of Oncology
Related Cases Studies
Competitive Intelligence
Market Assessment
Product Assessment
Epidemiology Assessment
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ovarian-cancer-market-growing-rapidly-estimates-delveinsight--bristol-myers-squibb-ono-pharmaceuticals-merck--co-abbvie-roche-clovis-oncology-are-expected-to-contribute-to-growth-301795322.html
